Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled time : 13:20 save search
BioSpace FDA Decision Tracker 2023: Emergent, Sanofi and AstraZeneca
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.31%
H: 0.44%
C: 0.2%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
fda sanofi
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 4.67%
H: 2.68%
C: 1.79%
health approval canada trial therapeutics phase 2
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Published: 2023-06-30 (Crawled : 13:20) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.19%
H: 5.92%
C: 4.64%
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 0.91%
H: 1.21%
C: 0.85%
vyvgart approval china
Masimo Announces FDA 510(k) Clearance of Radius VSM™
Published: 2023-06-05 (Crawled : 13:20) - biospace.com/
MASI | $134.77 -0.85% -0.85% 350K
|
Health Technology
|
| O: -1.53%
H: 2.49%
C: 2.43%
fda clearance
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Published: 2023-06-01 (Crawled : 13:20) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.45%
H: 5.5%
C: 2.49%
briumvi approval sclerosis treatment therapeutics
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Published: 2023-06-01 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
lynparza approved cancer treatment plus
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
Published: 2023-05-22 (Crawled : 13:20) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 8.62%
H: 29.37%
C: 11.9%
vafseo disease kidney anemia approval treatment dialysis
NeoVolta Approved for Partnership by GoodLeap, the Top U.S. Financer for Solar and Sustainable Tech
Published: 2023-05-04 (Crawled : 13:20) - neovolta.com
NEOV | $1.83 -1.61% -1.64% 38K
|
|
| O: -0.01%
H: 0.01%
C: -0.73%
partnership approved solar
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
Published: 2023-04-14 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
tepezza fda disease approval update thyroid eye therapeutics
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
Published: 2023-04-13 (Crawled : 13:20) - biospace.com/
SABS | $4.46 0.22% 890
|
|
| O: 81.58%
H: 18.84%
C: 9.99%
sab-176 fda granted influenza designation immunotherapy fast track designation
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 1.68%
H: 3.7%
C: 0.91%
rgx-202 fda candidate treatment designation duchenne therapy fast track designation
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.35%
C: -0.12%
hyqvia fda children approval
PPL Corporation subsidiary Rhode Island Energy gains regulatory approval for $290 million to strengthen network safety, reliability and resilience
Published: 2023-03-30 (Crawled : 13:20) - prnewswire.com
PPL M | $27.02 1.5% 0.0% 4.9M
|
Utilities
|
| O: 0.4%
H: 0.49%
C: -0.33%
energy approval corporation network
CCI approves acquisition of share capital of NSPIRA Management Services Pvt Ltd by Puneet Kothapa, Ponguru Sindhura & Ponguru Sharani – AffairsCloud.com
Published: 2023-03-28 (Crawled : 13:20) - spacfeed.com
AUUD | $1.94 -12.61% -14.43% 180K
|
Technology Services
|
| O: 0.0%
H: 0.0%
C: -7.04%
management services acquisition
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Published: 2023-03-27 (Crawled : 13:20) - biospace.com/
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 1.3%
H: 0.38%
C: -5.2%
ocu400 fda approval treatment ongoing trial
State of Arizona Approves DarkPulse, Inc. Subsidiary, TJM Electronics West, Inc., Trade Name Application for DarkPulse Electronics Manufacturing
Published: 2023-03-21 (Crawled : 13:20) - prnewswire.com
DPLS | $0.0009 81.82% 6.4M
|
Information
|
| O: 0.0%
H: 14.71%
C: 0.0%
state electronics application
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
Published: 2023-03-15 (Crawled : 13:20) - globenewswire.com
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: -1.66%
H: 1.77%
C: 1.37%
treatment vyvgart approval
Crescent Point Receives Approval for Normal Course Issuer Bid
Published: 2023-03-07 (Crawled : 13:20) - prnewswire.com
CPG | $8.69 2.84% -0.92% 5.5M
|
Energy Minerals
|
| O: -0.14%
H: 1.1%
C: -3.17%
crescent approval
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Published: 2023-03-07 (Crawled : 13:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.12%
H: 0.0%
C: -1.26%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.11%
H: 0.05%
C: -1.21%
meeting novartis
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: 78.62%
H: 27.05%
C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.